Answers are grounded in this paper and cite their sources.
Real-world evidence reveals chemo-immunotherapy effectiveness in advanced non-squamous NSCLC, suggesting KRAS mutation may influence outcomes.
mutation showed a potential negative predictive role in advanced nsq-NSCLC treated with first-line chemo-immunotherapy. The impact of co-mutations and post-progression outcomes warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Leonetti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: